Publications by authors named "I De Dios"

Introduction: Advancements in sequencing technologies have significantly improved clinical genetic testing, yet the diagnostic yield remains around 30-40%. Emerging sequencing technologies are now being deployed in the clinical setting to address the remaining diagnostic gap.

Methods: We tested whether short-read genome sequencing could increase diagnostic yield in individuals enrolled into the UCI-GREGoR research study, who had suspected Mendelian conditions and prior inconclusive clinical genetic testing.

View Article and Find Full Text PDF

Background: Social isolation measures by the COVID-19 pandemic have impacted teaching work. In an "Emergency Remote Teaching" (ERT) context, it is relevant to investigate the factors that affect teachers' self-efficacy.

Methods: A total of 289 teachers from schools in southern Spain have participated in this study.

View Article and Find Full Text PDF

Background: Homologous recombination deficiency (HRD) is the hallmark of breast cancer gene 1/2 ()-mutated tumors and the unique biomarker for predicting response to double-strand break (DSB)-inducing drugs. The demonstration of HRD in tumors with mutations in genes other than is considered the best biomarker of potential response to these DSB-inducer drugs.

Objectives: We explored the potential of developing a practical approach to predict in any tumor the presence of HRD that is similar to that seen in tumors with mutations using next-generation sequencing (NGS) along with machine learning (ML).

View Article and Find Full Text PDF

Diagnosis and classification of tumors is increasingly dependent on biomarkers. RNA expression profiling using next-generation sequencing provides reliable and reproducible information on the biology of cancer. This study investigated targeted transcriptome and artificial intelligence for differential diagnosis of hematologic and solid tumors.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness of targeted next generation sequencing (NGS) for identifying chromosomal abnormalities in patients with myeloid neoplasms using plasma cell-free DNA (cfDNA) samples from 2821 patients.
  • Results showed that 54.5% of samples had mutations associated with neoplasms, with distinct rates of abnormalities observed in myeloid (59%) and lymphoid (41%) neoplasms, and a strong concordance between cfDNA NGS results and traditional bone marrow cytogenetic data.
  • The research concludes that liquid biopsy through targeted NGS is a reliable method for detecting chromosomal abnormalities, potentially offering an alternative to invasive bone marrow biopsies for monitoring
View Article and Find Full Text PDF